1. Home
  2. FUND vs BNTC Comparison

FUND vs BNTC Comparison

Compare FUND & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FUND

Sprott Focus Trust Inc.

HOLD

Current Price

$9.97

Market Cap

303.4M

Sector

Finance

ML Signal

HOLD

Logo Benitec Biopharma Inc.

BNTC

Benitec Biopharma Inc.

HOLD

Current Price

$11.83

Market Cap

360.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUND
BNTC
Founded
1988
1995
Country
Canada
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
303.4M
360.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
FUND
BNTC
Price
$9.97
$11.83
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$27.67
AVG Volume (30 Days)
19.6K
70.8K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
6.64%
N/A
EPS Growth
N/A
80.94
EPS
0.93
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.71
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.39
$9.85
52 Week High
$10.47
$16.76

Technical Indicators

Market Signals
Indicator
FUND
BNTC
Relative Strength Index (RSI) 44.41 55.94
Support Level $9.87 $11.40
Resistance Level $10.07 $12.01
Average True Range (ATR) 0.18 0.64
MACD -0.04 0.12
Stochastic Oscillator 3.90 84.98

Price Performance

Historical Comparison
FUND
BNTC

About FUND Sprott Focus Trust Inc.

Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, the Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.

About BNTC Benitec Biopharma Inc.

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

Share on Social Networks: